Bayer Aktiengesellschaft BAYN.DE
Composite 39/100; the shares have moved about 42% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 14/100 — a strong mark against it.
Momentum ranks 83/100 — a strong point in its favour. Valuation ranks 54/100 — a slight point in its favour.
Growth ranks 14/100 — a strong mark against it. Balance-sheet strength ranks 25/100 — a strong mark against it. Quality ranks 29/100 — a moderate mark against it.
What the company does Bayer is a diversified life-science company with three segments: Pharmaceuticals (prescription drugs in cardiology, oncology, and women’s health), Consumer Health (OTC medicines and supplements), and Crop Science (crop protection, seeds, and digital ag solutions).
Key financials Bayer’s profitability metrics are mixed: ROE -6.9%, ROA 3.6%, ROCE 0.9%, gross margin 59.9%, operating margin 26.3%, and net margin -4.8%. Leverage is high (Debt/Equity 1.34, Net debt/EBITDA 3.17) with weak interest coverage (0.25) and current ratio (1.05).
Stock health Momentum is strong over 3m 29%, 6m 9%, and 12m 77%, but RSI(14) at 58 suggests limited near-term upside. Income yield is negligible at 0.2% with a payout ratio of 163.3%.
Price vs fair value Bayer trades at a PREMIUM of 53.30% versus our fair-value estimate of 22.51 and at a discount of 13.86% versus the 12-month target of 54.92. - Fair-value gap reflects weak fundamentals (ROE -6.9%, net margin -4.8%) versus premium valuation. - Analyst target implies 14% upside, supported by momentum (RSI 58, 12m +77%). - Recent ag-sector headlines highlight competitive pressures (Bloomberg, 2026-07-29).
Looking forward Forward P/E of 10.33 and EV/EBITDA of 23.36 imply a market pricing in recovery, but execution risks remain high given weak profitability and high leverage. Growth in Crop Science and Pharmaceuticals will be key to closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.